Depixus MAGNA One™: Unveiling the Dynamics of Biomolecular Interactions
At Depixus™, we are redefining the future of molecular science with our groundbreaking and award-winning Magnetic Force Spectroscopy (MFS) technology. MAGNA One™, powered by state-of-the-art MFS technology, provides scientists with real-time insights into thousands of individual biomolecular interactions occurring simultaneously.
With MFS technology, scientists can move beyond the limitations of bulk binding assays such as Surface Plasmon Resonance (SPR) or Isothermal Titration Calorimetry (ITC). These conventional methods offer snapshots of interactions based on averages. Our MFS technology shifts the paradigm by delivering real-time, single-molecule resolution, at scale. MAGNA One enables dynamic, continuous visualization, capturing real-time ligand-target interactions as they happen.
Unlocking New Biological Insights with Depixus MAGNA One
The ability to study biological processes at the level of individual interactions rather than population averages opens a window into a previously inaccessible world of biological detail. Here’s how Depixus MAGNA One is transforming our understanding of biomolecular interactions:
Molecular Heterogeneity
Our system allows researchers to observe subtle molecular variations within populations, revealing how these differences can influence biology in profound ways. By distinguishing these variations, scientists can better understand molecular heterogeneity. This capability is crucial for fields like drug discovery, where gaining insights into target interactions can guide the development of highly specific therapies.
Molecular Dynamics
Researchers can visualize real-time changes in molecular conformation. Our technology provides a direct view of how ligand binding and other molecular events affect structure and function. This information offers valuable insights into the kinetics of binding events, making it possible to study the intricacies of how drugs interact with their targets over time, an essential factor in drug efficacy.
Rare Events
The Depixus technology can detect molecular interactions that occur rarely but may play essential roles in biological systems. These rare events, often missed by traditional methods, can hold critical information about cellular mechanisms and signaling pathways. With MFS technology, scientists can explore these interactions, uncovering insights that could pave the way for breakthrough treatments across a wide range of diseases.
A New Era in Molecular Biology and Therapeutics
Depixus MAGNA One is a game-changing tool, offering researchers a powerful leap forward in their work. With its unparalleled ability to visualize biomolecular interactions in real time, it sheds light on the hidden complexities of biology. From drug discovery to biophysics research, this innovative technology is ready to drive the next generation of therapeutic breakthroughs and to deepen our understanding of the molecular mechanisms that shape life.
Email steve.klose@depixus.com or visit our website depixus.com to explore a range of valuable resources to fuel your research journey further.
About Drug Discovery Innovation Programme 2025
Drug Discovery Innovation Programme is an invitation-only and one of the best platforms to learn the latest insights and develop lasting business relationships.
This year’s Drug Discovery Innovation Programme will highlight the challenges discovery pipelines have faced due to COVID-19 and will put a spotlight on thec adoption of technology to finding the solutions.
With over 100+ attendees, learn how modernization in R&D processes is fundamentally changing what the drug discovery research will look like in the next two to five years.
So, join us in 2025 for an in-person experience and 2-days of top-level strategic content and the current scientific insights, networking, and discussions from leading global pharmaceutical R&D executives.
Companies in attendance for 2025 will include Servier Pharmaceuticals, Monte Rosa Therapeutics, University of Oxford, WPD Pharmaceuticals, AISA Therapeutics, Anima Biotech, PDC*line Pharma, Eli Lillly and Company, Symphogen, IRB Barcelona, Axonis Therapeutics, Genentech, Arakis Therapeutics, Johnson & Johnson, Amgen, Revitale Pharma, Progenra Inc, CERo Therapeutics, Merck and much more.